Clinical trials: Management, Risk
Diabetic Subjects With Hospital Stays
Impact of COVID-19 Infection and Confinement on Diabetic Ulcer Management and Amputation Risk
In the context of the COVID-19 pandemic, a number of factors, including the lockdown that was imposed to limit the spread of infection, the fear of being contaminated during hospital consultations and the difficulty in accessing…
- Trial name
- COROPIEDIAB (NCT04891276)
- Testing
- Data collection
- Where
- France
- Volunteers
- 3,300,000 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Managing Type 1 and High Risk Type 2 Diabetes in the Hospital Setting: Glucose as a Vital Sign
This program will provide patients with type 1 and high risk type 2 diabetes the safest hospitalization by using wireless continuous glucose monitoring devices (CGM) to track their glucose parameters in real-time similar to other…
- Trial name
- CGM (NCT03068273)
- Testing
- Real-time CGM data
- Where
- United States
- Volunteers
- 157 people
- Sponsor
- Scripps Whittier Diabetes Institute
Heart Failure
Risk Assessment and Comparative Effectiveness of Left Ventricular Assist Device (LVAD) and Medical Management
The purpose of this study is to evaluate and compare the effectiveness of the HeartMate II (HM II) Left Ventricular Assist Device (LVAD) support versus OMM in ambulatory NYHA Class IIIB/IV heart failure patients who are not…
- Trial name
- ROADMAP (NCT01452802)
- Testing
- HM II (HeartMate II LVAD), OMM (Optimal Medical Management)
- Where
- 52 sites in United States
- Volunteers
- 200 people
- Sponsor
- Abbott Medical Devices
Fibrosis, Renal Impairment
Safety of Gadovist in Renally Impaired Patients
Patients with moderate to severe renal impairment scheduled for a magnetic resonance imaging (MRI) scan and injection with a contrast agent, Gadovist, will be asked to participate.
- Trial name
- GRIP (NCT00828737)
- Testing
- Gadobutrol (Gadovist, BAY86-4875)
- Where
- 70 sites in Australia, Austria and 8 more
- Volunteers
- 927 people
- Sponsor
- Bayer
Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
This study will evaluate the safety and efficacy of intravesical administration of detalimogene (EG-70) in the bladder and its effect on bladder tumors in patients with NMIBC.
- Conditions
- Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ, Non-muscle Invasive Bladder Cancer
- Trial name
- NCT04752722
- Testing
- EG-70 (phase 1), EG-70 (phase 2) Master Protocol, Surfactant Bladder Pre-Rinse and EG-70 (Substudy)
- Where
- 102 sites in United States, Australia and 8 more
- Volunteers
- 350 people
- Sponsor
- enGene, Inc.
Long COVID
PERCEIVE-Outreach: A Scalable, Risk-Based Model for Managing Persistent Cardiovascular Impact in Long COVID
Some people who had COVID-19 continue to have symptoms for weeks, months, or even years after their infection. This is often called "Long COVID" or Post-Acute Sequelae of SARS-CoV-2 (PASC).
- Trial name
- NCT07661862
- Testing
- PERCEIVE-Outreach Disease Management Program
- Where
- 2 sites in Australia
- Volunteers
- 577 people
- Sponsor
- University of Tasmania
Pregnancy
Active Management Of Risk In Pregnancy At Term to Reduce Rate of Cesarean Deliveries
This is a prospective randomized cohort study of obstetric patients from Paley clinic at AEMC and from other affiliated obstetric clinics.
- Trial name
- NCT00598260
- Testing
- induction of labor
- Where
- United States
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Albert Einstein Healthcare Network
Dyslipidemia, Hypertension
A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk
The purpose of this study is to investigate whether an aggressive multi-risk factor management strategy (Caduet plus therapeutic lifestyle changes (TLC) regimen) will result in greater percentage of patients achieving blood…
- Trial name
- TOGETHER (NCT00412113)
- Testing
- Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination
- Where
- 51 sites in United States
- Volunteers
- 245 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Chronic Disease
Intensive Management of At-risk Patients
The purpose of this study is to assess if intensive management of at-risk participants, utilizing longitudinal patient tracking, proactive outreach, multidisciplinary action planning and careful outcomes monitoring, will lead to…
- Trial name
- NCT04456725
- Testing
- Intensive management, Control
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- CareMore Health, San Bernardino
Wound Heal
Postoperative Wounds With Delayed Healing Risk of Clinical Trial Registration
this study aims to optimize the components of TIME CDST based on clinical practice and apply the optimized elements to the management of wounds with delayed healing risk after hip arthroplasty to identify and design the key steps…
- Trial name
- NCT06272097
- Testing
- Intervention program based on TIME-CDST tool led by wound specialist nurses, A routine wound care program
- Volunteers
- 492 people
- Sponsor
- Danni Feng
Ischemic Stroke, Embolic Stroke of Undetermined Source
SENIOR: Stroke Prevention in the Elderly by Patent Foramen Ovale closuRe vs Anticoagulation
Patent foramen ovale (PFO) is an important mechanism of embolic stroke of undetermined source (ESUS). Current guidelines recommend PFO closure for high-risk PFO in patients younger than 60 years, and a recent retrospective cohort…
- Conditions
- Ischemic Stroke, Embolic Stroke of Undetermined Source, Patent Foramen Ovale (PFO), Elderly
- Trial name
- SENIOR (NCT07479147)
- Testing
- PFO closure, Medication
- Where
- 3 sites in Taiwan
- Volunteers
- 400 people
- Sponsor
- Taichung Veterans General Hospital
Spontaneous Subarachnoid Hemorrhage
Nursing Risk Management in Emergency SAH Surgery Using Healthcare Failure Mode and Effect Analysis(HFMEA)
The investigators are testing whether a new nurse-led safety program (HFMEA) lowers problems during emergency brain-aneurysm surgery better than usual care.
- Trial name
- NCT07315048
- Testing
- HFMEA-based nursing-risk programme
- Where
- China
- Volunteers
- 156 people
- Sponsor
- West China Hospital
Osteoporosis
Study and Follow-up of the Clinical Effectiveness and Comparative Safety of Biosimilar Teriparatide in the Management of Postmenopausal or Senile.
Non-interventional observational prospective follow-up study of cohorts of patients with Previous diagnosis of Osteoporosis with high risk of fractures, with/without previous fractures and treatment with bone formers (biosimilar…
- Trial name
- ESECTO (NCT05369013)
- Where
- 10 sites in Spain
- Volunteers
- 188 people
- Sponsor
- STADA, Spain
Mental Disorders, Severe
Transmural Collaborative Care Model for CVRM and Medication Review for Patients Using Antipsychotics
Currently, monitoring of usage and effects of antipsychotic treatment and cardiovascular risk screening in patients with severe mental illness or antipsychotic treatment is not sufficient.
- Trial name
- TACTIC (NCT05647980)
- Testing
- TACTIC
- Where
- Netherlands
- Volunteers
- 480 people
- Sponsor
- Radboud University Medical Center
Primary Care
Risk Management in Primary Care
The proposed research is a prospective, non-comparative study based on a qualitative method, comprising a literature review followed by 2 successive series of Focus Groups with users and healthcare professionals of primary care…
- Trial name
- eGERISSEP (NCT06484933)
- Testing
- Focus groups of health professionals and users of primary care
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Hospices Civils de Lyon
Schizophrenia
The Effect of a Community-based LAT-treated Management Model on the Violence Risk of Patients With Schizophrenia
This is a 49 weeks open-label randomized controlled study. Patients with schizophrenia and violence risk will be enrolled in the study.
- Trial name
- NCT03434210
- Testing
- LAT-treated Community Model, care as usual
- Where
- China
- Volunteers
- 110 people
- Sponsor
- Yi Li MD, PhD
Ischemia, Myocardial, Risk Factor, Cardiovascular
Risk Profiling for Patients With Isolated or Combined Coronary and Cerebral Ischemia, and Current Management Status
This study will delineate the risk profile of patients with isolated cerebral or coronary ischemia and those with combined disease.
- Conditions
- Ischemia, Myocardial, Risk Factor, Cardiovascular, Ischemia, Cerebral
- Trial name
- NCT02989077
- Volunteers
- 3,000 people
- Sponsor
- Egyptian Cerebro-Cardio-Vascular Association
Patients Treated With Methadone
Methadone Administration in Critically Ill Patients in the Intensive Care Unit and Risk of Prolonged QTc and Cardiac Arrythmia
Continuous infusion of short-acting synthetic opioids, primarily remifentanil, is widely used for anesthesia and analgesia in ventilated patients in the intensive care unit (ICU) due to its short half-life, which is independent…
- Trial name
- NCT07892677
- Testing
- ICU patients treated with methadone
- Where
- Israel
- Volunteers
- 300 people
- Sponsor
- Meir Medical Center
Caries
Longitudinal Follow-up of High Viscosity Glassionomer IonoStar Plus Versus a Composite Bulk X-tra-Fil Combined With Futurabond U (Splith Mouth Study): Reunion Island, Circus of Mafate
The main objective is the longitudinal follow-up and comparison of the maintenance of the dental filling materials up to 24 months using the HVGIC IonoStar Plus versus Bulk X-Tra -Fil composite (Futurabond U adhesive system).
- Trial name
- CVB (NCT03568253)
- Testing
- Caries treatment
- Where
- France
- Volunteers
- 65 people
- Sponsor
- University Hospital, Montpellier
Cardiovascular Diseases
Primary Care Audit of Global Risk Management
1. Assessing the perception of Canadian Primary Care Physicians towards global cardiovascular risk assessment. 2. Correlating physician perceptions to actual practice data, gathered via a retrospective chart audit. 3.
- Trial name
- PARADIGM (NCT00950703)
- Where
- Canada
- Volunteers
- 3,015 people, healthy volunteers welcome
- Sponsor
- Canadian Collaborative Research Network